nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—lung cancer	0.186	1	CbGaD
Bortezomib—SLC31A1—Cisplatin—lung cancer	0.145	0.37	CbGbCtD
Bortezomib—CYP1A1—Gefitinib—lung cancer	0.0292	0.0744	CbGbCtD
Bortezomib—CYP1A1—Erlotinib—lung cancer	0.0173	0.044	CbGbCtD
Bortezomib—CYP2C19—Gefitinib—lung cancer	0.0141	0.036	CbGbCtD
Bortezomib—CYP2C19—Teniposide—lung cancer	0.0137	0.0349	CbGbCtD
Bortezomib—PTGS1—Etoposide—lung cancer	0.0125	0.0318	CbGbCtD
Bortezomib—CYP2C9—Gefitinib—lung cancer	0.0118	0.03	CbGbCtD
Bortezomib—CYP2C9—Teniposide—lung cancer	0.0114	0.0291	CbGbCtD
Bortezomib—CYP2D6—Gefitinib—lung cancer	0.0108	0.0274	CbGbCtD
Bortezomib—CYP2C8—Erlotinib—lung cancer	0.00997	0.0254	CbGbCtD
Bortezomib—CYP2C8—Paclitaxel—lung cancer	0.00913	0.0233	CbGbCtD
Bortezomib—CYP2D6—Vinorelbine—lung cancer	0.00828	0.0211	CbGbCtD
Bortezomib—CYP1A2—Erlotinib—lung cancer	0.00772	0.0197	CbGbCtD
Bortezomib—CYP3A4—Topotecan—lung cancer	0.00748	0.019	CbGbCtD
Bortezomib—CYP2C8—Etoposide—lung cancer	0.00721	0.0184	CbGbCtD
Bortezomib—CYP3A4—Gefitinib—lung cancer	0.00684	0.0174	CbGbCtD
Bortezomib—CYP3A4—Teniposide—lung cancer	0.00663	0.0169	CbGbCtD
Bortezomib—CYP2C9—Paclitaxel—lung cancer	0.00637	0.0162	CbGbCtD
Bortezomib—CYP2D6—Erlotinib—lung cancer	0.00636	0.0162	CbGbCtD
Bortezomib—CYP1A2—Etoposide—lung cancer	0.00558	0.0142	CbGbCtD
Bortezomib—CYP3A4—Vinorelbine—lung cancer	0.00527	0.0134	CbGbCtD
Bortezomib—CYP2C9—Cisplatin—lung cancer	0.00512	0.013	CbGbCtD
Bortezomib—CYP2D6—Vinblastine—lung cancer	0.00511	0.013	CbGbCtD
Bortezomib—CYP3A4—Crizotinib—lung cancer	0.00419	0.0107	CbGbCtD
Bortezomib—CYP3A4—Erlotinib—lung cancer	0.00404	0.0103	CbGbCtD
Bortezomib—CYP3A4—Paclitaxel—lung cancer	0.0037	0.00943	CbGbCtD
Bortezomib—CYP3A4—Irinotecan—lung cancer	0.00365	0.0093	CbGbCtD
Bortezomib—CYP3A4—Vinblastine—lung cancer	0.00325	0.00827	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—lung cancer	0.00314	0.00799	CbGbCtD
Bortezomib—PSMD1—mammary gland—lung cancer	0.00302	0.0397	CbGeAlD
Bortezomib—CYP3A4—Etoposide—lung cancer	0.00292	0.00745	CbGbCtD
Bortezomib—CYP3A4—Docetaxel—lung cancer	0.00268	0.00682	CbGbCtD
Bortezomib—PSMD2—mammary gland—lung cancer	0.00267	0.0352	CbGeAlD
Bortezomib—CTSG—respiratory system—lung cancer	0.00249	0.0328	CbGeAlD
Bortezomib—PSMA1—respiratory system—lung cancer	0.00239	0.0315	CbGeAlD
Bortezomib—PSMA1—epithelium—lung cancer	0.002	0.0263	CbGeAlD
Bortezomib—PSMB2—mammary gland—lung cancer	0.002	0.0263	CbGeAlD
Bortezomib—CYP3A4—Doxorubicin—lung cancer	0.00199	0.00508	CbGbCtD
Bortezomib—CTSG—trachea—lung cancer	0.00184	0.0242	CbGeAlD
Bortezomib—PSMD2—respiratory system—lung cancer	0.00178	0.0234	CbGeAlD
Bortezomib—CTSG—cardiac atrium—lung cancer	0.00173	0.0228	CbGeAlD
Bortezomib—PSMD1—bronchus—lung cancer	0.00165	0.0218	CbGeAlD
Bortezomib—PSMD1—trachea—lung cancer	0.00149	0.0195	CbGeAlD
Bortezomib—PSMD2—bronchus—lung cancer	0.00147	0.0193	CbGeAlD
Bortezomib—CTSG—bone marrow—lung cancer	0.00146	0.0192	CbGeAlD
Bortezomib—PSMB8—bronchus—lung cancer	0.00146	0.0192	CbGeAlD
Bortezomib—PSMA1—bone marrow—lung cancer	0.0014	0.0185	CbGeAlD
Bortezomib—PSMD1—cardiac atrium—lung cancer	0.0014	0.0184	CbGeAlD
Bortezomib—PSMB1—respiratory system—lung cancer	0.00137	0.018	CbGeAlD
Bortezomib—PSMB2—respiratory system—lung cancer	0.00133	0.0175	CbGeAlD
Bortezomib—CTSG—lung—lung cancer	0.00132	0.0174	CbGeAlD
Bortezomib—PSMD2—trachea—lung cancer	0.00132	0.0173	CbGeAlD
Bortezomib—PSMB8—trachea—lung cancer	0.00131	0.0172	CbGeAlD
Bortezomib—PSMB5—bronchus—lung cancer	0.00129	0.0169	CbGeAlD
Bortezomib—PSMA1—lung—lung cancer	0.00127	0.0167	CbGeAlD
Bortezomib—PSMD2—cardiac atrium—lung cancer	0.00124	0.0163	CbGeAlD
Bortezomib—PSMD1—bone marrow—lung cancer	0.00118	0.0155	CbGeAlD
Bortezomib—PSMB5—trachea—lung cancer	0.00116	0.0152	CbGeAlD
Bortezomib—SLC31A1—respiratory system—lung cancer	0.00115	0.0152	CbGeAlD
Bortezomib—PSMB1—bronchus—lung cancer	0.00112	0.0148	CbGeAlD
Bortezomib—PSMB2—bronchus—lung cancer	0.0011	0.0144	CbGeAlD
Bortezomib—PSMB5—cardiac atrium—lung cancer	0.00109	0.0143	CbGeAlD
Bortezomib—PSMD1—lung—lung cancer	0.00107	0.014	CbGeAlD
Bortezomib—PSMD2—bone marrow—lung cancer	0.00104	0.0137	CbGeAlD
Bortezomib—PSMB8—bone marrow—lung cancer	0.00104	0.0136	CbGeAlD
Bortezomib—PSMB1—trachea—lung cancer	0.00101	0.0133	CbGeAlD
Bortezomib—PSMB2—trachea—lung cancer	0.000985	0.013	CbGeAlD
Bortezomib—PSMD2—Afatinib—Gefitinib—lung cancer	0.00095	0.281	CbGdCrCtD
Bortezomib—SLC31A1—bronchus—lung cancer	0.00095	0.0125	CbGeAlD
Bortezomib—PSMB1—cardiac atrium—lung cancer	0.000949	0.0125	CbGeAlD
Bortezomib—PSMD2—lung—lung cancer	0.000945	0.0124	CbGeAlD
Bortezomib—PSMB8—lung—lung cancer	0.00094	0.0124	CbGeAlD
Bortezomib—PSMB2—cardiac atrium—lung cancer	0.000925	0.0122	CbGeAlD
Bortezomib—PSMB5—bone marrow—lung cancer	0.000916	0.0121	CbGeAlD
Bortezomib—CTSG—lymph node—lung cancer	0.000906	0.0119	CbGeAlD
Bortezomib—PSMA1—lymph node—lung cancer	0.000869	0.0114	CbGeAlD
Bortezomib—SLC31A1—trachea—lung cancer	0.000853	0.0112	CbGeAlD
Bortezomib—PSMB5—lung—lung cancer	0.00083	0.0109	CbGeAlD
Bortezomib—SLC31A1—cardiac atrium—lung cancer	0.000801	0.0105	CbGeAlD
Bortezomib—PSMB1—bone marrow—lung cancer	0.000801	0.0105	CbGeAlD
Bortezomib—PSMB2—bone marrow—lung cancer	0.000781	0.0103	CbGeAlD
Bortezomib—PSMD1—lymph node—lung cancer	0.00073	0.00961	CbGeAlD
Bortezomib—PSMB1—lung—lung cancer	0.000726	0.00955	CbGeAlD
Bortezomib—PSMB2—lung—lung cancer	0.000708	0.00931	CbGeAlD
Bortezomib—SLC31A1—bone marrow—lung cancer	0.000677	0.0089	CbGeAlD
Bortezomib—PSMD2—lymph node—lung cancer	0.000647	0.00851	CbGeAlD
Bortezomib—PSMB8—lymph node—lung cancer	0.000643	0.00846	CbGeAlD
Bortezomib—CYP2C8—mammary gland—lung cancer	0.000637	0.00839	CbGeAlD
Bortezomib—SLC31A1—lung—lung cancer	0.000613	0.00807	CbGeAlD
Bortezomib—PSMB8—Podofilox—Teniposide—lung cancer	0.000608	0.18	CbGdCrCtD
Bortezomib—PSMB5—lymph node—lung cancer	0.000568	0.00747	CbGeAlD
Bortezomib—CYP2C9—mammary gland—lung cancer	0.000566	0.00745	CbGeAlD
Bortezomib—PSMB1—lymph node—lung cancer	0.000496	0.00653	CbGeAlD
Bortezomib—PSMB2—lymph node—lung cancer	0.000484	0.00637	CbGeAlD
Bortezomib—SLC31A1—lymph node—lung cancer	0.000419	0.00552	CbGeAlD
Bortezomib—PSMB2—Azacitidine—Gemcitabine—lung cancer	0.000407	0.12	CbGdCrCtD
Bortezomib—CYP1A2—respiratory system—lung cancer	0.000398	0.00523	CbGeAlD
Bortezomib—CYP1A1—respiratory system—lung cancer	0.000392	0.00516	CbGeAlD
Bortezomib—PSMB8—Vincristine—Vinorelbine—lung cancer	0.000387	0.114	CbGdCrCtD
Bortezomib—PSMB8—Vinorelbine—Vinblastine—lung cancer	0.000362	0.107	CbGdCrCtD
Bortezomib—PSMB8—Podofilox—Etoposide—lung cancer	0.000362	0.107	CbGdCrCtD
Bortezomib—PTGS1—respiratory system—lung cancer	0.000344	0.00453	CbGeAlD
Bortezomib—CYP1A1—epithelium—lung cancer	0.000328	0.00431	CbGeAlD
Bortezomib—CYP1A1—bronchus—lung cancer	0.000323	0.00425	CbGeAlD
Bortezomib—PSMB8—Vincristine—Vinblastine—lung cancer	0.00031	0.0914	CbGdCrCtD
Bortezomib—CYP1A1—trachea—lung cancer	0.00029	0.00381	CbGeAlD
Bortezomib—PTGS1—epithelium—lung cancer	0.000288	0.00379	CbGeAlD
Bortezomib—CYP1A1—cardiac atrium—lung cancer	0.000272	0.00358	CbGeAlD
Bortezomib—PTGS1—trachea—lung cancer	0.000255	0.00335	CbGeAlD
Bortezomib—PTGS1—cardiac atrium—lung cancer	0.000239	0.00315	CbGeAlD
Bortezomib—CYP1A2—lung—lung cancer	0.000211	0.00278	CbGeAlD
Bortezomib—CYP1A1—lung—lung cancer	0.000208	0.00274	CbGeAlD
Bortezomib—PTGS1—lung—lung cancer	0.000183	0.00241	CbGeAlD
Bortezomib—CYP1A1—lymph node—lung cancer	0.000142	0.00187	CbGeAlD
Bortezomib—PTGS1—lymph node—lung cancer	0.000125	0.00165	CbGeAlD
Bortezomib—Pain—Paclitaxel—lung cancer	2.55e-05	0.000126	CcSEcCtD
Bortezomib—Constipation—Paclitaxel—lung cancer	2.55e-05	0.000126	CcSEcCtD
Bortezomib—Confusional state—Docetaxel—lung cancer	2.55e-05	0.000126	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—lung cancer	2.53e-05	0.000126	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—lung cancer	2.53e-05	0.000126	CcSEcCtD
Bortezomib—Oedema—Docetaxel—lung cancer	2.52e-05	0.000125	CcSEcCtD
Bortezomib—Anaphylactic shock—Docetaxel—lung cancer	2.52e-05	0.000125	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—lung cancer	2.52e-05	0.000125	CcSEcCtD
Bortezomib—Pruritus—Gemcitabine—lung cancer	2.52e-05	0.000125	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—lung cancer	2.51e-05	0.000125	CcSEcCtD
Bortezomib—Infection—Docetaxel—lung cancer	2.51e-05	0.000125	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—lung cancer	2.51e-05	0.000124	CcSEcCtD
Bortezomib—Feeling abnormal—Etoposide—lung cancer	2.5e-05	0.000124	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—lung cancer	2.5e-05	0.000124	CcSEcCtD
Bortezomib—Diarrhoea—Irinotecan—lung cancer	2.5e-05	0.000124	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—lung cancer	2.49e-05	0.000123	CcSEcCtD
Bortezomib—Gastrointestinal pain—Etoposide—lung cancer	2.48e-05	0.000123	CcSEcCtD
Bortezomib—Shock—Docetaxel—lung cancer	2.48e-05	0.000123	CcSEcCtD
Bortezomib—Nervous system disorder—Docetaxel—lung cancer	2.48e-05	0.000123	CcSEcCtD
Bortezomib—Thrombocytopenia—Docetaxel—lung cancer	2.47e-05	0.000123	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—lung cancer	2.47e-05	0.000123	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—lung cancer	2.47e-05	0.000123	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—lung cancer	2.47e-05	0.000123	CcSEcCtD
Bortezomib—Tachycardia—Docetaxel—lung cancer	2.46e-05	0.000122	CcSEcCtD
Bortezomib—Feeling abnormal—Paclitaxel—lung cancer	2.45e-05	0.000122	CcSEcCtD
Bortezomib—Skin disorder—Docetaxel—lung cancer	2.45e-05	0.000122	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—lung cancer	2.45e-05	0.000122	CcSEcCtD
Bortezomib—Hypersensitivity—Cisplatin—lung cancer	2.44e-05	0.000121	CcSEcCtD
Bortezomib—Gastrointestinal pain—Paclitaxel—lung cancer	2.44e-05	0.000121	CcSEcCtD
Bortezomib—Diarrhoea—Gemcitabine—lung cancer	2.43e-05	0.000121	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—lung cancer	2.43e-05	0.000121	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—lung cancer	2.42e-05	0.00012	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—lung cancer	2.42e-05	0.00012	CcSEcCtD
Bortezomib—Dizziness—Irinotecan—lung cancer	2.42e-05	0.00012	CcSEcCtD
Bortezomib—Urticaria—Etoposide—lung cancer	2.41e-05	0.00012	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—lung cancer	2.41e-05	0.00012	CcSEcCtD
Bortezomib—Anorexia—Docetaxel—lung cancer	2.41e-05	0.000119	CcSEcCtD
Bortezomib—Abdominal pain—Etoposide—lung cancer	2.4e-05	0.000119	CcSEcCtD
Bortezomib—Body temperature increased—Etoposide—lung cancer	2.4e-05	0.000119	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—lung cancer	2.4e-05	0.000119	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—lung cancer	2.4e-05	0.000119	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—lung cancer	2.39e-05	0.000119	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—lung cancer	2.39e-05	0.000119	CcSEcCtD
Bortezomib—Asthenia—Cisplatin—lung cancer	2.38e-05	0.000118	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—lung cancer	2.38e-05	0.000118	CcSEcCtD
Bortezomib—Urticaria—Paclitaxel—lung cancer	2.37e-05	0.000117	CcSEcCtD
Bortezomib—Hypotension—Docetaxel—lung cancer	2.36e-05	0.000117	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—lung cancer	2.36e-05	0.000117	CcSEcCtD
Bortezomib—Abdominal pain—Paclitaxel—lung cancer	2.35e-05	0.000117	CcSEcCtD
Bortezomib—Body temperature increased—Paclitaxel—lung cancer	2.35e-05	0.000117	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—lung cancer	2.34e-05	0.000116	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—lung cancer	2.33e-05	0.000116	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—lung cancer	2.32e-05	0.000115	CcSEcCtD
Bortezomib—Vomiting—Irinotecan—lung cancer	2.32e-05	0.000115	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—lung cancer	2.32e-05	0.000115	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—lung cancer	2.31e-05	0.000115	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—lung cancer	2.31e-05	0.000115	CcSEcCtD
Bortezomib—Rash—Irinotecan—lung cancer	2.3e-05	0.000114	CcSEcCtD
Bortezomib—Dermatitis—Irinotecan—lung cancer	2.3e-05	0.000114	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Docetaxel—lung cancer	2.3e-05	0.000114	CcSEcCtD
Bortezomib—Chills—Methotrexate—lung cancer	2.3e-05	0.000114	CcSEcCtD
Bortezomib—Headache—Irinotecan—lung cancer	2.29e-05	0.000114	CcSEcCtD
Bortezomib—Insomnia—Docetaxel—lung cancer	2.28e-05	0.000113	CcSEcCtD
Bortezomib—Diarrhoea—Cisplatin—lung cancer	2.27e-05	0.000113	CcSEcCtD
Bortezomib—Paraesthesia—Docetaxel—lung cancer	2.27e-05	0.000113	CcSEcCtD
Bortezomib—Vomiting—Gemcitabine—lung cancer	2.26e-05	0.000112	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—lung cancer	2.26e-05	0.000112	CcSEcCtD
Bortezomib—Dyspnoea—Docetaxel—lung cancer	2.25e-05	0.000112	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—lung cancer	2.24e-05	0.000111	CcSEcCtD
Bortezomib—Rash—Gemcitabine—lung cancer	2.24e-05	0.000111	CcSEcCtD
Bortezomib—Dermatitis—Gemcitabine—lung cancer	2.24e-05	0.000111	CcSEcCtD
Bortezomib—Hypersensitivity—Etoposide—lung cancer	2.24e-05	0.000111	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—lung cancer	2.23e-05	0.000111	CcSEcCtD
Bortezomib—Erythema—Methotrexate—lung cancer	2.23e-05	0.000111	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—lung cancer	2.23e-05	0.000111	CcSEcCtD
Bortezomib—Headache—Gemcitabine—lung cancer	2.23e-05	0.000111	CcSEcCtD
Bortezomib—Dyspepsia—Docetaxel—lung cancer	2.22e-05	0.00011	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—lung cancer	2.22e-05	0.00011	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—lung cancer	2.22e-05	0.00011	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—lung cancer	2.21e-05	0.00011	CcSEcCtD
Bortezomib—Decreased appetite—Docetaxel—lung cancer	2.19e-05	0.000109	CcSEcCtD
Bortezomib—Hypersensitivity—Paclitaxel—lung cancer	2.19e-05	0.000109	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—lung cancer	2.19e-05	0.000109	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—lung cancer	2.18e-05	0.000108	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—lung cancer	2.18e-05	0.000108	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Docetaxel—lung cancer	2.18e-05	0.000108	CcSEcCtD
Bortezomib—Asthenia—Etoposide—lung cancer	2.18e-05	0.000108	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—lung cancer	2.18e-05	0.000108	CcSEcCtD
Bortezomib—Fatigue—Docetaxel—lung cancer	2.18e-05	0.000108	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—lung cancer	2.17e-05	0.000108	CcSEcCtD
Bortezomib—Nausea—Irinotecan—lung cancer	2.17e-05	0.000108	CcSEcCtD
Bortezomib—Pain—Docetaxel—lung cancer	2.16e-05	0.000107	CcSEcCtD
Bortezomib—Constipation—Docetaxel—lung cancer	2.16e-05	0.000107	CcSEcCtD
Bortezomib—Back pain—Methotrexate—lung cancer	2.16e-05	0.000107	CcSEcCtD
Bortezomib—Pruritus—Etoposide—lung cancer	2.15e-05	0.000107	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—lung cancer	2.14e-05	0.000106	CcSEcCtD
Bortezomib—Asthenia—Paclitaxel—lung cancer	2.14e-05	0.000106	CcSEcCtD
Bortezomib—Nausea—Gemcitabine—lung cancer	2.11e-05	0.000105	CcSEcCtD
Bortezomib—Vomiting—Cisplatin—lung cancer	2.11e-05	0.000105	CcSEcCtD
Bortezomib—Pruritus—Paclitaxel—lung cancer	2.11e-05	0.000105	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—lung cancer	2.1e-05	0.000104	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—lung cancer	2.1e-05	0.000104	CcSEcCtD
Bortezomib—Rash—Cisplatin—lung cancer	2.09e-05	0.000104	CcSEcCtD
Bortezomib—Dermatitis—Cisplatin—lung cancer	2.09e-05	0.000104	CcSEcCtD
Bortezomib—Feeling abnormal—Docetaxel—lung cancer	2.08e-05	0.000103	CcSEcCtD
Bortezomib—Diarrhoea—Etoposide—lung cancer	2.08e-05	0.000103	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—lung cancer	2.07e-05	0.000103	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—lung cancer	2.07e-05	0.000103	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—lung cancer	2.07e-05	0.000103	CcSEcCtD
Bortezomib—Gastrointestinal pain—Docetaxel—lung cancer	2.06e-05	0.000103	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—lung cancer	2.06e-05	0.000102	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—lung cancer	2.06e-05	0.000102	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—lung cancer	2.06e-05	0.000102	CcSEcCtD
Bortezomib—Diarrhoea—Paclitaxel—lung cancer	2.04e-05	0.000101	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—lung cancer	2.01e-05	9.99e-05	CcSEcCtD
Bortezomib—Malaise—Methotrexate—lung cancer	2.01e-05	9.98e-05	CcSEcCtD
Bortezomib—Dizziness—Etoposide—lung cancer	2.01e-05	9.97e-05	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—lung cancer	2e-05	9.95e-05	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—lung cancer	2e-05	9.95e-05	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—lung cancer	2e-05	9.92e-05	CcSEcCtD
Bortezomib—Body temperature increased—Docetaxel—lung cancer	2e-05	9.91e-05	CcSEcCtD
Bortezomib—Abdominal pain—Docetaxel—lung cancer	2e-05	9.91e-05	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—lung cancer	2e-05	9.91e-05	CcSEcCtD
Bortezomib—Chills—Doxorubicin—lung cancer	1.99e-05	9.88e-05	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—lung cancer	1.98e-05	9.84e-05	CcSEcCtD
Bortezomib—Dizziness—Paclitaxel—lung cancer	1.97e-05	9.78e-05	CcSEcCtD
Bortezomib—Nausea—Cisplatin—lung cancer	1.97e-05	9.78e-05	CcSEcCtD
Bortezomib—Cough—Methotrexate—lung cancer	1.95e-05	9.66e-05	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—lung cancer	1.94e-05	9.65e-05	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—lung cancer	1.93e-05	9.59e-05	CcSEcCtD
Bortezomib—Vomiting—Etoposide—lung cancer	1.93e-05	9.59e-05	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—lung cancer	1.93e-05	9.59e-05	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—lung cancer	1.93e-05	9.59e-05	CcSEcCtD
Bortezomib—Rash—Etoposide—lung cancer	1.92e-05	9.51e-05	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—lung cancer	1.91e-05	9.5e-05	CcSEcCtD
Bortezomib—Headache—Etoposide—lung cancer	1.9e-05	9.45e-05	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—lung cancer	1.9e-05	9.45e-05	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—lung cancer	1.9e-05	9.43e-05	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—lung cancer	1.9e-05	9.43e-05	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—lung cancer	1.9e-05	9.43e-05	CcSEcCtD
Bortezomib—Vomiting—Paclitaxel—lung cancer	1.89e-05	9.4e-05	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—lung cancer	1.89e-05	9.39e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.89e-05	9.36e-05	CcSEcCtD
Bortezomib—Rash—Paclitaxel—lung cancer	1.88e-05	9.33e-05	CcSEcCtD
Bortezomib—Dermatitis—Paclitaxel—lung cancer	1.88e-05	9.32e-05	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—lung cancer	1.88e-05	9.31e-05	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—lung cancer	1.87e-05	9.27e-05	CcSEcCtD
Bortezomib—Headache—Paclitaxel—lung cancer	1.87e-05	9.27e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Docetaxel—lung cancer	1.86e-05	9.24e-05	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—lung cancer	1.86e-05	9.22e-05	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—lung cancer	1.83e-05	9.11e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—lung cancer	1.82e-05	9.04e-05	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—lung cancer	1.82e-05	9.03e-05	CcSEcCtD
Bortezomib—Asthenia—Docetaxel—lung cancer	1.81e-05	8.99e-05	CcSEcCtD
Bortezomib—Infection—Methotrexate—lung cancer	1.81e-05	8.98e-05	CcSEcCtD
Bortezomib—Nausea—Etoposide—lung cancer	1.8e-05	8.96e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—lung cancer	1.79e-05	8.89e-05	CcSEcCtD
Bortezomib—Pruritus—Docetaxel—lung cancer	1.79e-05	8.87e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—lung cancer	1.78e-05	8.86e-05	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—lung cancer	1.78e-05	8.86e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—lung cancer	1.78e-05	8.85e-05	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—lung cancer	1.77e-05	8.81e-05	CcSEcCtD
Bortezomib—Nausea—Paclitaxel—lung cancer	1.77e-05	8.78e-05	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—lung cancer	1.77e-05	8.78e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—lung cancer	1.76e-05	8.73e-05	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—lung cancer	1.74e-05	8.64e-05	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—lung cancer	1.73e-05	8.61e-05	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—lung cancer	1.73e-05	8.61e-05	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—lung cancer	1.73e-05	8.6e-05	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—lung cancer	1.73e-05	8.58e-05	CcSEcCtD
Bortezomib—Diarrhoea—Docetaxel—lung cancer	1.73e-05	8.58e-05	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—lung cancer	1.71e-05	8.47e-05	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—lung cancer	1.7e-05	8.44e-05	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—lung cancer	1.7e-05	8.43e-05	CcSEcCtD
Bortezomib—Cough—Doxorubicin—lung cancer	1.68e-05	8.37e-05	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—lung cancer	1.67e-05	8.31e-05	CcSEcCtD
Bortezomib—Dizziness—Docetaxel—lung cancer	1.67e-05	8.29e-05	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—lung cancer	1.67e-05	8.28e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—lung cancer	1.66e-05	8.23e-05	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—lung cancer	1.65e-05	8.17e-05	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—lung cancer	1.64e-05	8.16e-05	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—lung cancer	1.64e-05	8.16e-05	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—lung cancer	1.64e-05	8.16e-05	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—lung cancer	1.64e-05	8.13e-05	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—lung cancer	1.63e-05	8.11e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.63e-05	8.11e-05	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—lung cancer	1.62e-05	8.06e-05	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—lung cancer	1.62e-05	8.06e-05	CcSEcCtD
Bortezomib—Vomiting—Docetaxel—lung cancer	1.61e-05	7.97e-05	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—lung cancer	1.6e-05	7.95e-05	CcSEcCtD
Bortezomib—Rash—Docetaxel—lung cancer	1.59e-05	7.9e-05	CcSEcCtD
Bortezomib—Dermatitis—Docetaxel—lung cancer	1.59e-05	7.9e-05	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—lung cancer	1.59e-05	7.89e-05	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—lung cancer	1.58e-05	7.85e-05	CcSEcCtD
Bortezomib—Headache—Docetaxel—lung cancer	1.58e-05	7.85e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—lung cancer	1.58e-05	7.82e-05	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—lung cancer	1.58e-05	7.82e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—lung cancer	1.57e-05	7.8e-05	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—lung cancer	1.57e-05	7.79e-05	CcSEcCtD
Bortezomib—Infection—Doxorubicin—lung cancer	1.57e-05	7.77e-05	CcSEcCtD
Bortezomib—Pain—Methotrexate—lung cancer	1.56e-05	7.73e-05	CcSEcCtD
Bortezomib—Shock—Doxorubicin—lung cancer	1.55e-05	7.7e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—lung cancer	1.55e-05	7.67e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—lung cancer	1.54e-05	7.66e-05	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—lung cancer	1.54e-05	7.64e-05	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—lung cancer	1.53e-05	7.6e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—lung cancer	1.52e-05	7.56e-05	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—lung cancer	1.5e-05	7.46e-05	CcSEcCtD
Bortezomib—Nausea—Docetaxel—lung cancer	1.5e-05	7.45e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—lung cancer	1.5e-05	7.45e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—lung cancer	1.49e-05	7.39e-05	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—lung cancer	1.47e-05	7.31e-05	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—lung cancer	1.45e-05	7.18e-05	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—lung cancer	1.44e-05	7.14e-05	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—lung cancer	1.44e-05	7.14e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.44e-05	7.13e-05	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—lung cancer	1.43e-05	7.08e-05	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—lung cancer	1.41e-05	7.03e-05	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—lung cancer	1.4e-05	6.98e-05	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—lung cancer	1.39e-05	6.89e-05	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—lung cancer	1.37e-05	6.8e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—lung cancer	1.36e-05	6.75e-05	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—lung cancer	1.36e-05	6.75e-05	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—lung cancer	1.35e-05	6.69e-05	CcSEcCtD
Bortezomib—Pain—Doxorubicin—lung cancer	1.35e-05	6.69e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—lung cancer	1.34e-05	6.66e-05	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—lung cancer	1.31e-05	6.48e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—lung cancer	1.3e-05	6.45e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—lung cancer	1.29e-05	6.4e-05	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—lung cancer	1.29e-05	6.39e-05	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—lung cancer	1.25e-05	6.22e-05	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—lung cancer	1.25e-05	6.18e-05	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—lung cancer	1.25e-05	6.18e-05	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—lung cancer	1.25e-05	6.18e-05	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—lung cancer	1.2e-05	5.97e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—lung cancer	1.16e-05	5.76e-05	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—lung cancer	1.16e-05	5.74e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—lung cancer	1.15e-05	5.7e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—lung cancer	1.15e-05	5.69e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—lung cancer	1.14e-05	5.66e-05	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—lung cancer	1.13e-05	5.61e-05	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—lung cancer	1.11e-05	5.54e-05	CcSEcCtD
Bortezomib—Nausea—Methotrexate—lung cancer	1.08e-05	5.37e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—lung cancer	1.08e-05	5.35e-05	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—lung cancer	1.04e-05	5.17e-05	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—lung cancer	1e-05	4.97e-05	CcSEcCtD
Bortezomib—Rash—Doxorubicin—lung cancer	9.94e-06	4.93e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—lung cancer	9.93e-06	4.93e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—lung cancer	9.87e-06	4.9e-05	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—lung cancer	9.36e-06	4.65e-05	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—lung cancer	2.58e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP2E1—lung cancer	2.57e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GCLC—lung cancer	2.56e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2A6—lung cancer	2.56e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—lung cancer	2.56e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—lung cancer	2.56e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—lung cancer	2.56e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	2.55e-06	1.81e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2E1—lung cancer	2.55e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—lung cancer	2.55e-06	1.81e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NQO1—lung cancer	2.55e-06	1.8e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—lung cancer	2.54e-06	1.8e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—lung cancer	2.54e-06	1.8e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—lung cancer	2.54e-06	1.8e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CREBBP—lung cancer	2.53e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—lung cancer	2.53e-06	1.79e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NQO1—lung cancer	2.52e-06	1.79e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAT—lung cancer	2.52e-06	1.78e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.5e-06	1.77e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKR1C1—lung cancer	2.5e-06	1.77e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—STK11—lung cancer	2.49e-06	1.77e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—lung cancer	2.49e-06	1.76e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—lung cancer	2.48e-06	1.76e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK3—lung cancer	2.47e-06	1.75e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK3—lung cancer	2.47e-06	1.75e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK3—lung cancer	2.47e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.47e-06	1.75e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—lung cancer	2.47e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.45e-06	1.73e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCB1—lung cancer	2.45e-06	1.73e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—lung cancer	2.44e-06	1.73e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—lung cancer	2.44e-06	1.73e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—lung cancer	2.44e-06	1.73e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ERCC2—lung cancer	2.44e-06	1.73e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK3—lung cancer	2.44e-06	1.73e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO1—lung cancer	2.43e-06	1.72e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—UGT1A1—lung cancer	2.43e-06	1.72e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.42e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—lung cancer	2.41e-06	1.7e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—lung cancer	2.4e-06	1.7e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—lung cancer	2.4e-06	1.7e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—lung cancer	2.4e-06	1.7e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TYMS—lung cancer	2.4e-06	1.7e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CD—lung cancer	2.4e-06	1.7e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.39e-06	1.69e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—lung cancer	2.38e-06	1.69e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—lung cancer	2.38e-06	1.69e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—lung cancer	2.38e-06	1.69e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—lung cancer	2.38e-06	1.69e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—lung cancer	2.38e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—lung cancer	2.37e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—lung cancer	2.37e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—lung cancer	2.37e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—lung cancer	2.36e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—lung cancer	2.35e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—lung cancer	2.35e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—lung cancer	2.35e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—lung cancer	2.35e-06	1.66e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.34e-06	1.66e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNG11—lung cancer	2.34e-06	1.66e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—lung cancer	2.32e-06	1.64e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—lung cancer	2.31e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—STK11—lung cancer	2.29e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—STK11—lung cancer	2.27e-06	1.61e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1A1—lung cancer	2.25e-06	1.6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAT—lung cancer	2.25e-06	1.59e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ERCC2—lung cancer	2.23e-06	1.58e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.23e-06	1.58e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDOA—lung cancer	2.23e-06	1.58e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—lung cancer	2.22e-06	1.57e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—lung cancer	2.22e-06	1.57e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—lung cancer	2.22e-06	1.57e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—lung cancer	2.2e-06	1.56e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—lung cancer	2.19e-06	1.55e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—lung cancer	2.19e-06	1.55e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—lung cancer	2.18e-06	1.55e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2E1—lung cancer	2.18e-06	1.54e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—lung cancer	2.18e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOA3—lung cancer	2.16e-06	1.53e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NQO1—lung cancer	2.16e-06	1.53e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TYMS—lung cancer	2.15e-06	1.52e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.13e-06	1.51e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—lung cancer	2.12e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—lung cancer	2.12e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.11e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOA1—lung cancer	2.11e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADCY1—lung cancer	2.11e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCG2—lung cancer	2.11e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—lung cancer	2.1e-06	1.49e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CB—lung cancer	2.09e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.09e-06	1.48e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—lung cancer	2.07e-06	1.47e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAT—lung cancer	2.07e-06	1.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HPGDS—lung cancer	2.06e-06	1.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO2—lung cancer	2.06e-06	1.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPP2R1B—lung cancer	2.05e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAT—lung cancer	2.05e-06	1.45e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—lung cancer	2.04e-06	1.45e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—lung cancer	2.04e-06	1.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—lung cancer	2.04e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.04e-06	1.44e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.02e-06	1.43e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—lung cancer	2.01e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1A1—lung cancer	2.01e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—lung cancer	2.01e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—lung cancer	2e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ERCC2—lung cancer	1.99e-06	1.41e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—lung cancer	1.99e-06	1.41e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—lung cancer	1.99e-06	1.41e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—lung cancer	1.99e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—lung cancer	1.99e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GCLC—lung cancer	1.98e-06	1.4e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2A6—lung cancer	1.98e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—lung cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—lung cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—lung cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TYMS—lung cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—lung cancer	1.97e-06	1.39e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TYMS—lung cancer	1.96e-06	1.39e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—lung cancer	1.95e-06	1.38e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—lung cancer	1.95e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—STK11—lung cancer	1.94e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—lung cancer	1.93e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOA1—lung cancer	1.93e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CG—lung cancer	1.92e-06	1.36e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—lung cancer	1.89e-06	1.34e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—lung cancer	1.89e-06	1.34e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—lung cancer	1.89e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO1—lung cancer	1.88e-06	1.33e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—lung cancer	1.86e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.85e-06	1.31e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1A1—lung cancer	1.85e-06	1.31e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ERCC2—lung cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1A1—lung cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—POMC—lung cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.82e-06	1.29e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ERCC2—lung cancer	1.82e-06	1.29e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—lung cancer	1.81e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—lung cancer	1.81e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—lung cancer	1.81e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—lung cancer	1.81e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—lung cancer	1.8e-06	1.27e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CREBBP—lung cancer	1.78e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—lung cancer	1.78e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CG—lung cancer	1.76e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAT—lung cancer	1.75e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.74e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOA1—lung cancer	1.72e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—EP300—lung cancer	1.72e-06	1.22e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—lung cancer	1.7e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CD—lung cancer	1.69e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2E1—lung cancer	1.68e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—POMC—lung cancer	1.68e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMS—lung cancer	1.67e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—lung cancer	1.67e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—lung cancer	1.67e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—lung cancer	1.67e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—lung cancer	1.67e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NQO1—lung cancer	1.66e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—lung cancer	1.65e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.65e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—lung cancer	1.64e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CREBBP—lung cancer	1.64e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOA1—lung cancer	1.59e-06	1.12e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CG—lung cancer	1.57e-06	1.12e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOA1—lung cancer	1.57e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1A1—lung cancer	1.57e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ERCC2—lung cancer	1.55e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CD—lung cancer	1.55e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—lung cancer	1.53e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.51e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—STK11—lung cancer	1.5e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—POMC—lung cancer	1.5e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CB—lung cancer	1.47e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—lung cancer	1.46e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CREBBP—lung cancer	1.46e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CG—lung cancer	1.45e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CG—lung cancer	1.44e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—lung cancer	1.39e-06	9.83e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CD—lung cancer	1.38e-06	9.81e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—POMC—lung cancer	1.38e-06	9.77e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—POMC—lung cancer	1.37e-06	9.68e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—lung cancer	1.37e-06	9.68e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CB—lung cancer	1.35e-06	9.57e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAT—lung cancer	1.35e-06	9.56e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOA1—lung cancer	1.34e-06	9.52e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CREBBP—lung cancer	1.34e-06	9.51e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—lung cancer	1.34e-06	9.49e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CREBBP—lung cancer	1.33e-06	9.43e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—lung cancer	1.31e-06	9.3e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMS—lung cancer	1.29e-06	9.14e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.29e-06	9.12e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—lung cancer	1.28e-06	9.04e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—lung cancer	1.28e-06	9.03e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—lung cancer	1.27e-06	9.02e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CD—lung cancer	1.27e-06	9.02e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CD—lung cancer	1.26e-06	8.94e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—lung cancer	1.26e-06	8.9e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—lung cancer	1.25e-06	8.83e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CG—lung cancer	1.23e-06	8.69e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—EP300—lung cancer	1.22e-06	8.61e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1A1—lung cancer	1.21e-06	8.56e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CB—lung cancer	1.21e-06	8.55e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ERCC2—lung cancer	1.2e-06	8.49e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—lung cancer	1.2e-06	8.47e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—lung cancer	1.17e-06	8.27e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—POMC—lung cancer	1.17e-06	8.27e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CREBBP—lung cancer	1.14e-06	8.06e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—EP300—lung cancer	1.11e-06	7.89e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CB—lung cancer	1.11e-06	7.86e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CB—lung cancer	1.1e-06	7.79e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—lung cancer	1.1e-06	7.79e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—lung cancer	1.09e-06	7.72e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CD—lung cancer	1.08e-06	7.64e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—lung cancer	1.06e-06	7.54e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—lung cancer	1.04e-06	7.39e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—lung cancer	1.04e-06	7.38e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA1—lung cancer	1.04e-06	7.35e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—EP300—lung cancer	9.94e-07	7.04e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—lung cancer	9.59e-07	6.79e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—lung cancer	9.51e-07	6.73e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CG—lung cancer	9.47e-07	6.71e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CB—lung cancer	9.4e-07	6.66e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—lung cancer	9.32e-07	6.6e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—EP300—lung cancer	9.15e-07	6.48e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—EP300—lung cancer	9.07e-07	6.42e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—POMC—lung cancer	9.01e-07	6.38e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—lung cancer	8.99e-07	6.37e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CREBBP—lung cancer	8.78e-07	6.22e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CD—lung cancer	8.33e-07	5.9e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—lung cancer	8.24e-07	5.84e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—lung cancer	8.22e-07	5.82e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—lung cancer	8.12e-07	5.75e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—EP300—lung cancer	7.75e-07	5.49e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—lung cancer	7.36e-07	5.21e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—lung cancer	7.34e-07	5.2e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CB—lung cancer	7.26e-07	5.14e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—lung cancer	7.19e-07	5.09e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—lung cancer	6.77e-07	4.79e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—lung cancer	6.73e-07	4.77e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—lung cancer	6.71e-07	4.75e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—lung cancer	6.27e-07	4.44e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—lung cancer	6.01e-07	4.26e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—EP300—lung cancer	5.98e-07	4.24e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—lung cancer	5.73e-07	4.06e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—lung cancer	5.53e-07	3.91e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—lung cancer	5.48e-07	3.88e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—lung cancer	4.68e-07	3.32e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—lung cancer	4.42e-07	3.13e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—lung cancer	3.61e-07	2.56e-06	CbGpPWpGaD
